Compare IPCA Labs with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DIVIS LABORATORIES - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DIVIS LABORATORIES IPCA LABS/
DIVIS LABORATORIES
 
P/E (TTM) x 30.2 50.4 59.8% View Chart
P/BV x 6.1 9.2 66.2% View Chart
Dividend Yield % 0.2 0.7 30.0%  

Financials

 IPCA LABS   DIVIS LABORATORIES
EQUITY SHARE DATA
    IPCA LABS
Mar-19
DIVIS LABORATORIES
Mar-19
IPCA LABS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0421,639 63.6%   
Low Rs5901,115 52.9%   
Sales per share (Unadj.) Rs298.6186.3 160.3%  
Earnings per share (Unadj.) Rs35.051.0 68.7%  
Cash flow per share (Unadj.) Rs49.457.3 86.2%  
Dividends per share (Unadj.) Rs3.0016.00 18.8%  
Dividend yield (eoy) %0.41.2 31.6%  
Book value per share (Unadj.) Rs247.1261.8 94.4%  
Shares outstanding (eoy) m126.35265.47 47.6%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.77.4 37.0%   
Avg P/E ratio x23.327.0 86.3%  
P/CF ratio (eoy) x16.524.0 68.7%  
Price / Book Value ratio x3.35.3 62.8%  
Dividend payout %8.631.4 27.3%   
Avg Mkt Cap Rs m103,108365,592 28.2%   
No. of employees `00013.411.8 113.5%   
Total wages/salary Rs m7,8745,423 145.2%   
Avg. sales/employee Rs Th2,807.04,175.1 67.2%   
Avg. wages/employee Rs Th585.8457.7 128.0%   
Avg. net profit/employee Rs Th329.01,141.8 28.8%   
INCOME DATA
Net Sales Rs m37,73249,463 76.3%  
Other income Rs m5771,556 37.1%   
Total revenues Rs m38,30951,019 75.1%   
Gross profit Rs m6,90118,718 36.9%  
Depreciation Rs m1,8241,689 108.0%   
Interest Rs m18935 539.1%   
Profit before tax Rs m5,46518,551 29.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0425,023 20.8%   
Profit after tax Rs m4,42213,527 32.7%  
Gross profit margin %18.337.8 48.3%  
Effective tax rate %19.127.1 70.4%   
Net profit margin %11.727.3 42.9%  
BALANCE SHEET DATA
Current assets Rs m23,77846,501 51.1%   
Current liabilities Rs m10,9758,468 129.6%   
Net working cap to sales %33.976.9 44.1%  
Current ratio x2.25.5 39.5%  
Inventory Days Days104131 79.3%  
Debtors Days Days6686 76.8%  
Net fixed assets Rs m20,36825,797 79.0%   
Share capital Rs m253531 47.6%   
"Free" reserves Rs m30,97168,962 44.9%   
Net worth Rs m31,22469,493 44.9%   
Long term debt Rs m1,4090-   
Total assets Rs m45,50780,383 56.6%  
Interest coverage x30.0531.0 5.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.6 134.7%   
Return on assets %10.116.9 60.1%  
Return on equity %14.219.5 72.8%  
Return on capital %17.326.7 64.8%  
Exports to sales %45.90-   
Imports to sales %16.624.6 67.4%   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,26612,187 51.4%   
Fx inflow Rs m17,30841,238 42.0%   
Fx outflow Rs m6,26612,405 50.5%   
Net fx Rs m11,04228,833 38.3%   
CASH FLOW
From Operations Rs m4,9239,543 51.6%  
From Investments Rs m-1,563-6,854 22.8%  
From Financial Activity Rs m-1,832-2,459 74.5%  
Net Cashflow Rs m1,528230 665.4%  

Share Holding

Indian Promoters % 45.9 52.0 88.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 11.8 96.6%  
FIIs % 25.3 19.0 133.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.2 101.2%  
Shareholders   36,892 31,796 116.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

BPCL March Quarter Results, Privatisation of State-Run Banks, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended their trading session marginally lower yesterday. Benchmark indices snapped their 6-day winning streak yesterday and edged lower tracking mixed global cues.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 4, 2020 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS